MoonLake Immunotherapeutics Net Income
| MLTX Stock | USD 15.51 0.74 5.01% |
As of the 8th of February, MoonLake Immunotherapeuti secures the Downside Deviation of 4.11, risk adjusted performance of 0.1129, and Mean Deviation of 3.88. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MoonLake Immunotherapeuti, as well as the relationship between them.
MoonLake Immunotherapeuti's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MoonLake Immunotherapeuti's valuation are provided below:We have found one hundred twenty available fundamental ratios for MoonLake Immunotherapeuti, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of MoonLake Immunotherapeuti last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 3.2 B in 2026. Enterprise Value is likely to rise to about 3 B in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -109.1 M | -103.7 M | |
| Net Loss | -109.1 M | -103.7 M | |
| Net Loss | -45 M | -42.7 M | |
| Net Loss | (2.18) | (2.28) | |
| Net Income Per E B T | 1.13 | 0.98 |
MoonLake | Net Income | Build AI portfolio with MoonLake Stock |
The evolution of Net Income for MoonLake Immunotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how MoonLake Immunotherapeuti compares to historical norms and industry peers.
Latest MoonLake Immunotherapeuti's Net Income Growth Pattern
Below is the plot of the Net Income of MoonLake Immunotherapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in MoonLake Immunotherapeuti financial statement analysis. It represents the amount of money remaining after all of MoonLake Immunotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is MoonLake Immunotherapeuti's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MoonLake Immunotherapeuti's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (121.24 M) | 10 Years Trend |
|
Net Income |
| Timeline |
MoonLake Net Income Regression Statistics
| Arithmetic Mean | (25,513,090) | |
| Coefficient Of Variation | (170.73) | |
| Mean Deviation | 35,366,495 | |
| Median | (90,838) | |
| Standard Deviation | 43,558,256 | |
| Sample Variance | 1897.3T | |
| Range | 118.8M | |
| R-Value | (0.77) | |
| Mean Square Error | 810.4T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (6,679,207) | |
| Total Sum of Squares | 30357.1T |
MoonLake Net Income History
Other Fundumenentals of MoonLake Immunotherapeuti
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
MoonLake Immunotherapeuti Net Income component correlations
MoonLake Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for MoonLake Immunotherapeuti is extremely important. It helps to project a fair market value of MoonLake Stock properly, considering its historical fundamentals such as Net Income. Since MoonLake Immunotherapeuti's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of MoonLake Immunotherapeuti's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of MoonLake Immunotherapeuti's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MoonLake Immunotherapeuti. Expected growth trajectory for MoonLake significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MoonLake Immunotherapeuti assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of MoonLake Immunotherapeuti is measured differently than its book value, which is the value of MoonLake that is recorded on the company's balance sheet. Investors also form their own opinion of MoonLake Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is MoonLake Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MoonLake Immunotherapeuti's market value can be influenced by many factors that don't directly affect MoonLake Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that MoonLake Immunotherapeuti's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MoonLake Immunotherapeuti represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, MoonLake Immunotherapeuti's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
MoonLake Immunotherapeuti 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MoonLake Immunotherapeuti's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MoonLake Immunotherapeuti.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in MoonLake Immunotherapeuti on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding MoonLake Immunotherapeutics or generate 0.0% return on investment in MoonLake Immunotherapeuti over 90 days. MoonLake Immunotherapeuti is related to or competes with Regenxbio, MBX Biosciences, Absci Corp, Verastem, MeiraGTx Holdings, Erasca, and Ventyx Biosciences. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies More
MoonLake Immunotherapeuti Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MoonLake Immunotherapeuti's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MoonLake Immunotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.11 | |||
| Information Ratio | 0.115 | |||
| Maximum Drawdown | 35.46 | |||
| Value At Risk | (6.36) | |||
| Potential Upside | 8.68 |
MoonLake Immunotherapeuti Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for MoonLake Immunotherapeuti's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MoonLake Immunotherapeuti's standard deviation. In reality, there are many statistical measures that can use MoonLake Immunotherapeuti historical prices to predict the future MoonLake Immunotherapeuti's volatility.| Risk Adjusted Performance | 0.1129 | |||
| Jensen Alpha | 0.7028 | |||
| Total Risk Alpha | 0.1816 | |||
| Sortino Ratio | 0.1766 | |||
| Treynor Ratio | 0.6233 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MoonLake Immunotherapeuti's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
MoonLake Immunotherapeuti February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1129 | |||
| Market Risk Adjusted Performance | 0.6333 | |||
| Mean Deviation | 3.88 | |||
| Semi Deviation | 3.65 | |||
| Downside Deviation | 4.11 | |||
| Coefficient Of Variation | 773.79 | |||
| Standard Deviation | 6.31 | |||
| Variance | 39.85 | |||
| Information Ratio | 0.115 | |||
| Jensen Alpha | 0.7028 | |||
| Total Risk Alpha | 0.1816 | |||
| Sortino Ratio | 0.1766 | |||
| Treynor Ratio | 0.6233 | |||
| Maximum Drawdown | 35.46 | |||
| Value At Risk | (6.36) | |||
| Potential Upside | 8.68 | |||
| Downside Variance | 16.91 | |||
| Semi Variance | 13.3 | |||
| Expected Short fall | (4.66) | |||
| Skewness | 2.45 | |||
| Kurtosis | 9.2 |
MoonLake Immunotherapeuti Backtested Returns
MoonLake Immunotherapeuti appears to be somewhat reliable, given 3 months investment horizon. MoonLake Immunotherapeuti has Sharpe Ratio of 0.12, which conveys that the firm had a 0.12 % return per unit of risk over the last 3 months. By analyzing MoonLake Immunotherapeuti's technical indicators, you can evaluate if the expected return of 0.77% is justified by implied risk. Please exercise MoonLake Immunotherapeuti's Downside Deviation of 4.11, mean deviation of 3.88, and Risk Adjusted Performance of 0.1129 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, MoonLake Immunotherapeuti holds a performance score of 9. The company secures a Beta (Market Risk) of 1.29, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MoonLake Immunotherapeuti will likely underperform. Please check MoonLake Immunotherapeuti's value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether MoonLake Immunotherapeuti's current price movements will revert.
Auto-correlation | 0.30 |
Below average predictability
MoonLake Immunotherapeutics has below average predictability. Overlapping area represents the amount of predictability between MoonLake Immunotherapeuti time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MoonLake Immunotherapeuti price movement. The serial correlation of 0.3 indicates that nearly 30.0% of current MoonLake Immunotherapeuti price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.3 | |
| Spearman Rank Test | 0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 3.71 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
MoonLake Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, MoonLake Immunotherapeutics reported net income of (121.24 Million). This is 135.53% lower than that of the Biotechnology sector and 273.09% lower than that of the Health Care industry. The net income for all United States stocks is 121.23% higher than that of the company.
MoonLake Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MoonLake Immunotherapeuti's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MoonLake Immunotherapeuti could also be used in its relative valuation, which is a method of valuing MoonLake Immunotherapeuti by comparing valuation metrics of similar companies.MoonLake Immunotherapeuti is currently under evaluation in net income category among its peers.
MoonLake Immunotherapeuti ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, MoonLake Immunotherapeuti's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to MoonLake Immunotherapeuti's managers, analysts, and investors.Environmental | Governance | Social |
MoonLake Immunotherapeuti Institutional Holders
Institutional Holdings refers to the ownership stake in MoonLake Immunotherapeuti that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of MoonLake Immunotherapeuti's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing MoonLake Immunotherapeuti's value.| Shares | Nuveen, Llc | 2025-06-30 | 791.6 K | Rtw Investments, Llc | 2025-06-30 | 741.1 K | Hood River Capital Management Llc | 2025-06-30 | 675.4 K | Vestal Point Capital Lp | 2025-06-30 | 550 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 529.2 K | Siren, L.l.c. | 2025-06-30 | 508.3 K | Balyasny Asset Management Llc | 2025-06-30 | 423.2 K | Blackrock Inc | 2025-06-30 | 327.3 K | Mpm Oncology Impact Management Lp | 2025-06-30 | 313.6 K | Bvf Inc | 2025-06-30 | 19.8 M | Cormorant Asset Management, Llc | 2025-06-30 | 8.5 M |
MoonLake Fundamentals
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 793.03 M | ||||
| Shares Outstanding | 70.85 M | ||||
| Shares Owned By Insiders | 10.80 % | ||||
| Shares Owned By Institutions | 62.30 % | ||||
| Number Of Shares Shorted | 7.18 M | ||||
| Price To Book | 3.80 X | ||||
| EBITDA | (141.71 M) | ||||
| Net Income | (121.24 M) | ||||
| Cash And Equivalents | 92.71 M | ||||
| Cash Per Share | 2.51 X | ||||
| Total Debt | 2.83 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.51 X | ||||
| Book Value Per Share | 4.54 X | ||||
| Cash Flow From Operations | (116.59 M) | ||||
| Short Ratio | 2.16 X | ||||
| Earnings Per Share | (3.33) X | ||||
| Target Price | 19.03 | ||||
| Number Of Employees | 100 | ||||
| Beta | 1.21 | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 477.93 M | ||||
| Retained Earnings | (235.59 M) | ||||
| Working Capital | 451.82 M | ||||
| Net Asset | 477.93 M |
About MoonLake Immunotherapeuti Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MoonLake Immunotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MoonLake Immunotherapeuti using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MoonLake Immunotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.